[1]
K. A. Ebrahimi et al., “Significance of KIT and PDGFRA mutations in gastric gastrointestinal stromal tumor imatinib-naive surgically treated patients”, Vojnosanit Pregl, vol. 76, no. 12, July 2021, doi: 10.2298/VSP180205048E.